EXASOL
9.2.2021 10:02:07 CET | Business Wire | Press release
For the fourth consecutive year, Exasol , the analytics database, has been named a customer experience and a vendor credibility Overall Leader in the Dresner Advisory Services Wisdom of Crowds® 2021 Analytical Data Infrastructure (ADI) Report . Exasol also achieved a perfect recommend score again - 100% of Exasol’s customers who participated in the report would recommend its analytics database. High placement in the upper-right quadrant confirms that customers receive high value and have strong confidence in Exasol.
In addition, Exasol was also ranked best-in-class for ten different measures, including reliability of technology, technical support and responsiveness, and integrity.
The Dresner 2021 ADI Market Study provides a detailed picture of perceptions, intentions, and realities associated with ADI platform choices. The report examines market preferences for ADI platforms including deployment and licensing priorities, data types, data modeling/management of data associated with ADI, and data preparation and loading priorities. It also covers leading choices in ADI development and deployment, as well as ADI interfaces and analytical features.
“We congratulate Exasol on maintaining a perfect recommend score for the fourth consecutive year from customers and receiving best-in-class in ten customer value measurement categories – demonstrating the value its customers perceive with its platform,” Howard Dresner, founder and chief research officer at Dresner Advisory Services. “Business and IT leaders require robust analytical data infrastructure systems more than ever to deliver business value during these unprecedented times.”
According to the Dresner ADI report, business intelligence (BI) related use cases—business reporting and dashboards, specifically—ranked as the top priority for ADI platforms. The appetite for traditional BI use cases continues to increase, as performance ranked as the highest priority for ADI platforms in 2021. Additionally, in-memory data capabilities are an important priority for more than 50% of respondents, and columnar data models surpass row-format based models for organizing analytical data.
The report also found that the majority of business functions prefer a cloud deployment versus on-premise software, but on-prem isn’t going away any time soon. It is still a priority for 40% of organizations. According to the report, respondents’ preferences are dictated by use cases, with some being more suited to cloud services and others to on-prem deployments. As a result, multiple buying centres are working with hybrid deployment models for ADI platforms, a preference that increases with company size.
“As a customer-obsessed organization, it is validation of our day-to-day work that our customers rate us so highly,” said Aaron Auld, CEO at Exasol. “Maintaining a perfect recommend score for the fourth consecutive year is as much as we can hope for and the least which we expect of ourselves. I’m incredibly proud of the Exasol team and the way they put all their energy into helping our customers on their analytics journey. Our outstanding results in the Dresner report are testament to that.”
To read the full report, visit our Dresner ADI 2021 page.
ENDS
About Exasol
The Exasol high-performance analytics database is built to run faster than any other database, delivering next-level performance, scale and ease of use. Analyze billions of rows in seconds; run high-performance analytics securely in the cloud or on-premise; deliver frictionless analytics with self-indexing that automatically tunes performance; and scale out analytics for one transparent price.
To learn more, please visit: www.exasol.com
About Dresner Advisory Services, LLC
Dresner Advisory Services
was formed by Howard Dresner, an independent analyst, author, lecturer, and business adviser. Dresner Advisory Services, LLC focuses on creating and sharing thought leadership for Business Intelligence (BI) and related areas.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005090/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom